ClinicalTrials.gg
RecruitingNCT05799482Updated Sep 21, 2023

Exploring the Experiences, Expectations and Preferences of Patients With the UHS COVID-19 Follow-up Clinic

An observational study in COVID-19, sponsored by University Hospital Southampton NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by University Hospital Southampton NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2023, 3 years ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 340 studies in COVID-19 with a site in United Kingdom — 17 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · United Kingdom.

Planned enrollment
152nd of 167
30 · median 296
Started
2023
with 11 others
Observational
167 of 340
9 open now
Primary completion
2023-10
later than 4 of 31 live
Registered
325th of 340
by date

Among the 340 studies in COVID-19 with a site in United Kingdom, this one is the 152nd largest by planned enrollment of the 167 observational ones that give a count, is one of 12 that started in 2023, is one of 167 observational ones, reaches primary completion later than 4 of the 31 other live ones, and was the 325th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

17 of the 340 studies in COVID-19 with a site in United Kingdom are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 340 studies in COVID-19 with a site in United Kingdom, or all of them as a file.
02

Study summary

People who are older, those who had underlying other health conditions and people living in poorer communities are at increased risk of complications and worse outcome from COVID-19. They are more likely to be admitted to hospital with this virus. In the UK in 2020, over 130,000 people were admitted to hospital with COVID-19. Whilst admission rates fell since then, there is a need to understand better the potential impact of the many symptoms resulting from a COVID-19 infection on patients and the health services. To achieve this, the respiratory team in the University Hospital set up a COVID-19 follow-up clinic for patients who had COVID-19 infection. In this clinic, for a period of 12 weeks patients have chest X-rays, blood tests and virtual medical consultations. The clinic has been running for three years.

This study will be conducted study to understand the expectations, preferences and experiences of patients who have been receiving care in the clinic. On one hand, patients who have received care in the clinic during the last yearwill be interviewed. On the other hand, patients who have been newly referred to the clinic will be interviewed before they start it and also after 12 weeks about how their expectations have been met. Patients will be identified by their clinical team and after consenting to take part in the study, they will be interviewed by qualitative researchers who will also analyse the interview data using scientific methods. The results of this study will help understanding whether changes are to be made to this clinic and also inform future similar services should they be needed.

Read the detailed description

The long-term consequences of COVID-19 remain unclear. People who are older, have medical comorbidities and those who live in areas of increased socio-economic deprivation are at increased risk of poor outcome and complications from COVID-19 (1).

In 2020, over 130,000 people have been admitted to hospital with COVID-19 in the UK (2). Whilst admission rates fell, the potential impact of 'post-COVID' syndromes on patients and the health services need longer-term further investigation.

The British Thoracic Society (BTS) COVID-19 Guidance advises follow-up of patients who had COVID-19, depending on whether the patient required intensive/higher care versus ward/community care.1. For mild/moderate disease, BTS recommends virtual follow-up with a chest X-ray (1). A wide range of symptoms and reduced HRQoL has been detected in these patients reinforcing the importance of a implementing a holistic approach advocated by the BTS and other guidelines (2).

The COVID follow-up service was set up in 2020 in the Southampton General Hospital to provide longer-term care to patients with COVID-19 chest symptoms. The changing nature of the pandemic and an extension of the cohort from patients discharged after hospital stay for COVID-19 infection to previously not hospitalised patients referred by GPs call for an evaluation of the COVID follow-up clinic to explore patient experiences, expectations, and preferences with this service.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The research population of interest for this study is patients followed up in the UHS COVID follow-up clinic following diagnosed COVID-19 infection. This will include all patients deemed appropriate by their clinical team to receive this clinical service

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or over
  • Must have had a diagnosis of COVID-19 infection
  • Must have been discharged from hospital following admission with Covid-19 infection OR
  • Must have been referred to by their GP and accepted into the UHS COVID follow-up clinic
  • Retrospective study arm: must have been receiving care in the UHS COVID follow-up clinic at any stage in the last 12 months
  • Prospective study arm: must be newly referred to UHS COVID follow-up clinic
  • Conversational level of English that does not require a translator
  • Giving written

Exclusion criteria

Exclusion Criteria:

  • Less than 18 years old
  • Not followed up at UHS post discharge from hospital after admission for COVID-19 infection OR
  • Not accepted into the UHS COVID follow-up clinic
  • Retrospective study arm: received care in the COVID follow-up clinic more than 12 months prior to enrolment in the study
  • Unwilling or unable to give
  • Unwilling or unable to participate in the interview
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retrospective cross-sectional arm

    One-to-one semi-structured interviews will be conducted with patients who have received care in the UHS COVID follow-up clinics in no more than 12 months prior to study enrolment. Interviews will be conducted at one time point

    Other: Qualitative Interview

  • Prospective, longitudinal arm

    One-to-one semi-structured interviews will be conducted with patients with confirmed prior COVID-19 infection who are scheduled to receive care in the UHS COVID follow-up clinics. Interviews will be conducted before attending the first clinic appointment (baseline) and after discharge from the clinic (at 12 weeks).

    Other: Qualitative Interview

Interventions

  • OtherQualitative Interview

    Qualitative, semi-structured interview

06

What researchers measure

Primary outcomes

  1. Qualitative Interview

    Experiences, preferences and expectations of patients receiving care in the UHS COVID-19 follow-up clinic

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • George PM, Barratt SL, Condliffe R, Desai SR, Devaraj A, Forrest I, Gibbons MA, Hart N, Jenkins RG, McAuley DF, Patel BV, Thwaite E, Spencer LG. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020 Nov;75(11):1009-1016. doi: 10.1136/thoraxjnl-2020-215314. Epub 2020 Aug 24. PubMed 32839287 ↗
  • Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, Noel A, Gunning S, Hatrick J, Hamilton S, Elvers KT, Hyams C, Bibby A, Moran E, Adamali HI, Dodd JW, Maskell NA, Barratt SL. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021 Apr;76(4):399-401. doi: 10.1136/thoraxjnl-2020-216086. Epub 2020 Dec 3. PubMed 33273026 ↗
  • Wallis TJ, Welham B, Kong A, Morelli T, Azim A, Horno J, Wilkinson M, Burke H, Freeman A, Wilkinson TM, Jones MG, Marshall BG. Predicting the risk of chest radiograph abnormality 12-weeks post hospitalisation with SARS CoV-2 PCR confirmed COVID-19. Respir Res. 2022 Oct 31;23(1):297. doi: 10.1186/s12931-022-02217-0. PubMed 36316730 ↗
  • Wallis TJM, Heiden E, Horno J, Welham B, Burke H, Freeman A, Dexter L, Fazleen A, Kong A, McQuitty C, Watson M, Poole S, Brendish NJ, Clark TW, Wilkinson TMA, Jones MG, Marshall BG. Risk factors for persistent abnormality on chest radiographs at 12-weeks post hospitalisation with PCR confirmed COVID-19. Respir Res. 2021 May 21;22(1):157. doi: 10.1186/s12931-021-01750-8. PubMed 34020644 ↗

Individual participant data

Plan to share: No — Throughout the study, the researchers will be working with the Public and Patient Involvement group to develop a dissemination strategy of the results to the study participants and other stakeholders and/or the public as appropriate.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Oct 2023, 2 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 2 months is below that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2023
First posted
Apr 5, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Oct 30, 2023
CompletionEst.
Apr 1, 2024
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05799482
Responsible party
Sponsor
First posted
Apr 5, 2023
Start date
Aug 1, 2023
Primary completion
Oct 30, 2023 (estimated)
Completion
Apr 1, 2024 (estimated)
Last update
Sep 21, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion